This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Acute polymorphic psychotic disorder without symptoms of schizophrenia조현병의 증상이 없는 급성 다형성 정신병장애 (급성다형성정신병)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: F23.0 (Acute polymorphic psychotic disorder without symptoms of schizophrenia) | Special Copayment Reduction: V161 (severe intractable disease, 5 years)
B. SynonymsCycloid psychosis without symptoms of schizophrenia, bouffée délirante without symptoms of schizophrenia
C. Adult onsetPossibility of first presenting in adulthood Very high — onset mainly in early to middle adulthood (20s-40s), often arising suddenly after an acute stressful event.
1. HistoryDerived from the concept of 'bouffée délirante' in French psychiatry; systematized as the F23 group in ICD-10; recognized as an acute psychosis with a favorable prognosis distinct from schizophrenia.
2. CausesAcute psychosocial stress (bereavement, job loss, immigration), sleep deprivation, transient surge of dopamine hyperactivity, interaction between underlying vulnerability (genetic, temperamental) and precipitating stress.
3. GeneticsLower genetic burden than schizophrenia; research on genetic factors related to predisposition to acute reactive psychosis is ongoing; possible sharing of schizophrenia spectrum genes in some patients.
4. General epidemiologyAnnual incidence of acute and transient psychotic disorders as a whole about 6-9 per 100,000 population; F23.0 has a somewhat higher incidence in relatively young adults and women; tends to be more common in developing countries.
5. PathophysiologySurge of cortisol and dopamine due to acute stress, limbic hyperactivity, increased vulnerability to psychosis with sleep deprivation, neuroplasticity mechanism explaining rapid recovery.
6. SymptomsAbrupt onset (within 2 weeks), rapidly changing polymorphic symptoms (hallucinations, delusions, mood swings, confusion), absence of schizophrenia-specific symptoms (Schneider first-rank symptoms), spontaneous recovery possible.
7. SignsSevere agitation, confusion, abrupt mood changes, rapid changes in polymorphic symptoms within a short time, absence of schizophrenia negative symptoms, lack of insight.
8. ScreeningImmediate psychiatric evaluation when acute psychotic symptoms appear; measuring severity with PANSS and BPRS; basic blood and imaging tests to exclude organic causes.
9. DiagnosisICD-10 F23.0: acute onset within 2 weeks, rapidly changing polymorphic symptoms, no schizophrenia-specific symptoms, course under 3 months; organic and substance-induced causes excluded.
10. TreatmentShort-term antipsychotics (initial acute phase); providing a safe environment; sleep and nutrition recovery; supportive psychotherapy; resolving stress precipitants; consider tapering medication after recovery.
11. PrognosisGood prognosis; complete recovery within several weeks to months is typical; relapse possible but chronicity rare; some transition to a diagnosis of schizophrenia or a mood disorder.
12. PreventionStress management and sleep hygiene education; education on recognizing relapse risk; establishing a plan for early access to care at relapse; support for vulnerable groups (immigrants, people with a previous episode).
13. ReferencesPillmann F, Haring A, Balzuweit S, Marneros A. Bouffée délirante and ICD-10 acute and transient psychoses. Australian & New Zealand Journal of Psychiatry. 2003 … and 9 other papers

1. History

The conceptual origin of acute polymorphic psychotic disorder without symptoms of schizophrenia (F23.0) can be found in 'bouffée délirante' (delusional outburst) described in 19th-century French psychiatry. The term was first used in 1893 by the French psychiatrist Valentin Magnan to describe an acute psychotic episode that arises suddenly and recovers completely within several weeks. Magnan argued that this state is a distinct clinical entity with a favorable prognosis, essentially different from dementia praecox (schizophrenia), which follows a chronic and deteriorating course.

In the French psychiatric tradition, bouffée délirante developed as an independent clinical unit, and it was emphasized that, unlike schizophrenia, it does not become chronic, complete recovery is possible, and even if it recurs, full functioning is maintained between episodes. This was a position in contrast to the German-British tradition, influenced by Kraepelin, which tended to view this state as a subtype or early manifestation of schizophrenia.

Up to ICD-9 (1978), these acute psychotic states were not classified into a consistent category, but in ICD-10 (1992) the F23 group (acute and transient psychotic disorders) was newly established through years of work by an international research team. In this process, related concepts from Danish, German, and French psychiatry (transient psychosis, reactive psychosis, bouffée délirante) were integrated, and the feature of 'polymorphic' was adopted as the core criterion. F23.0 was defined as the subtype whose main characteristic is rapidly changing polymorphic symptoms without schizophrenia-specific symptoms (Schneider first-rank symptoms, thought disorder, etc.).

The DSM system has no category directly corresponding to F23.0, and 'Brief Psychotic Disorder (F23)' in DSM-5 is the most similar. In DSM-5, brief psychotic disorder describes a psychotic episode lasting at least 1 day and less than 1 month with subsequent full recovery, and specification of whether stress is a precipitant (specifier) is required. In ICD-11 (2022), the F23 group was restructured and the criteria for acute and transient psychotic disorder and its subtypes were made clearer.


2. Causes

As the cause of F23.0, the predisposition-stress model is accepted as the most persuasive explanatory framework. It is a model in which abrupt psychosocial stress triggers a transient psychotic episode in a vulnerable individual.

Acute stressors: acute psychosocial stressors such as the death of a close person (bereavement), job loss, bankruptcy, divorce, immigration, diagnosis of a serious physical illness, and experience of a natural disaster are known as precipitants of onset in the F23 group. The temporal association between such stressors and the onset of psychosis is specified as a specifier ('with associated acute stress') in the ICD-10 F23 group classification. DSM-5 also requires specifying, for brief psychotic disorder, whether there is a marked stressor.

Sleep deprivation: there is evidence that sleep deprivation sharply raises vulnerability to psychosis. In situations such as postpartum psychosis, jet lag stress, and shift work, sleep deprivation is associated with onset of the F23 group. Sleep deprivation causes hyperactivity of the dopamine system and increased amygdala reactivity, raising vulnerability to psychosis.

Neurobiological mechanism: acute stress activates the hypothalamic-pituitary-adrenal axis (HPA axis) and sharply raises cortisol. Hypercortisolemia has a toxic effect on hippocampal neurons and causes a state of limbic dopamine hypersensitivity, triggering the phenomenon of aberrant salience. This transient dopamine surge triggers an acute psychotic episode, and when the stress is resolved and cortisol normalizes, symptoms also recover quickly.

Individual vulnerability factors: underlying genetic vulnerability (some schizophrenia spectrum genes), prior mental health vulnerability, history of substance use (cannabis, etc.), and personality traits (high neuroticism, low resilience) explain individual differences in response to the same stress. The postpartum period is known to be a vulnerable period for onset of F23.0 in particular, because hormonal fluctuation, sleep deprivation, role changes, and other combined stresses are concentrated.


3. Genetics

The genetics of F23.0 is estimated to have a lower genetic contribution than schizophrenia, with the role of environmental and stress factors relatively more prominent. However, underlying genetic vulnerability is not completely excluded.

Family studies: family studies of the F23 group as a whole do not present consistent results, but some studies report that the risk of mood disorders (bipolar disorder, major depressive disorder) in first-degree relatives of these patients is higher than that of schizophrenia. This suggests that F23.0 may have a genetic basis closer to mood spectrum disorders than to schizophrenia. When there is a family history of schizophrenia, the risk of transition to schizophrenia after an F23 episode is high.

Twin studies: there are no large twin studies of brief psychotic disorder and the F23 group. In general twin studies on the characteristics of acute reactive psychosis, heritability is estimated at about 40-50%, lower than that of schizophrenia (about 80%).

Incidence in immigrants: there are epidemiological studies showing that the incidence of the F23 group is markedly higher in immigrants (especially first-generation immigrants). Together with the stress effect of the immigration experience itself, this supports the hypothesis that the cultural and genetic background of immigrants interacts with a vulnerability to specific psychotic reactivity. There are Western studies reporting a particularly high incidence of the F23 group in West African Caribbean immigrants, which emphasizes the importance of gene-environment interaction.

Clinical significance: the characteristic of F23.0, in which environmental stress plays a more important role than genetic vulnerability, suggests that stress management and environmental adjustment may be effective for prevention and relapse prevention. In patients with a family history of schizophrenia, the subsequent course is followed closely to monitor the possibility of transition to schizophrenia.


4. General epidemiology

The description centers on the epidemiological characteristics of acute and transient psychotic disorders (F23 group) as a whole, including F23.0. Independent epidemiological data for F23.0 are limited.

Incidence: the annual incidence of the F23 group as a whole is reported as about 6-9 per 100,000 population. This is lower than the annual incidence of schizophrenia (15-20 per 100,000 population). Incidence varies greatly with study region and diagnostic system, and tends to be higher in developing countries than in developed countries. In a multinational study led by the World Psychiatric Association (WPA), the F23 group showed significantly higher incidence in Africa, South Asia, and Central America than in Western Europe and North America.

Sex differences: in the F23 group as a whole, the incidence in women is reported to be slightly higher than or similar to that in men. Specifically for F23.0, postpartum psychosis (postpartum F23 episodes) occurs only in women, so the proportion of women is somewhat higher. Young women, especially women in the postpartum period, are a specific vulnerable group for onset of the F23 group.

Age of onset: the F23 group mainly develops in young adults in their 20s-40s and is characterized by a slightly later age of onset than schizophrenia. It can also occur in the elderly, but in this case organic causes (dementia, etc.) must be excluded first.

Status in Korea: in Korea, independent epidemiological data on the F23 group are lacking, but in Health Insurance Review & Assessment Service data, the number of patients treated under the F23 group is reported at the level of tens of thousands per year. Attention is needed particularly to occurrence in groups with high socioeconomic stress (job-seeking failure, business failure, immigrants).


5. Pathophysiology

The pathophysiology of F23.0 is explained as a process in which transient neurobiological abnormalities due to acute stress cause psychotic symptoms and rapid normalization occurs after the stress is resolved.

HPA axis activation and dopamine hypersensitivity: acute psychosocial stress immediately activates the hypothalamic-pituitary-adrenal axis (HPA axis), causing a cortisol surge. Cortisol acts on the limbic system (amygdala, hippocampus), especially on dopamine neurons of the ventral tegmental area (VTA), transiently inducing mesolimbic dopamine hyperactivity. This dopamine hyperactivity causes aberrant salience, producing hallucinations, delusions, and confusion. After the stress is resolved, the HPA axis normalizes, dopamine hyperactivity subsides, and symptoms resolve quickly.

Sleep deprivation and vulnerability to psychosis: sleep deprivation reduces prefrontal dopamine regulatory function and stimulates hypothalamic cortisol secretion, sharply increasing vulnerability to psychosis. That sleep deprivation is one of the main precipitants of psychotic episodes in postpartum psychosis supports this mechanism. The clinical observation that sleep recovery contributes greatly to symptom relief is also consistent with this mechanism.

Neuroplasticity and rapid recovery: the tendency of F23.0 toward rapid spontaneous recovery suggests that, unlike the chronic neuropathology of schizophrenia (prefrontal cortical gray matter reduction, decreased synaptic density), a transient functional abnormality can recover without structural change. High neuroplasticity in young adults is proposed as one of the factors enabling rapid recovery. A transient decrease followed by rapid recovery of BDNF (brain-derived neurotrophic factor) may be involved in this process.

Mechanism of polymorphic symptoms: the characteristic polymorphism of F23.0 (rapidly changing hallucinations, delusions, confusion, and mood changes) reflects the short-term, unstable nature of dopamine hyperactivity. Unlike chronic schizophrenia, in which dopamine dysregulation is fixed and shows a stable symptom pattern, in F23.0 dopamine hyperactivity is not sustained, so symptoms change rapidly and ultimately resolve.


6. Symptoms

The core symptoms of F23.0 are abrupt onset and rapidly changing polymorphic psychotic symptoms, and the absence of schizophrenia-specific symptoms (Schneider first-rank symptoms) is an important point of distinction from F23.1.

Pattern of onset: abrupt onset with symptoms peaking within 2 weeks is characteristic. A dramatic pattern of onset is observed in which a person who previously maintained normal functioning suddenly shows severe psychotic symptoms, with no prodromal symptoms or only a very brief prodrome. There is often acute psychosocial stress (bereavement, job loss, immigration, etc.) immediately beforehand.

Specific content of polymorphic symptoms: hallucinations (mainly auditory and visual) appear but, unlike in schizophrenia, are not persistent or fixed and their content changes rapidly. Delusions appear but are unsystematized, confused, and transient. Emotional changes are extreme, with extreme fear, happiness, confusion, and anger replacing one another rapidly. Disorientation or a state of confusion may accompany. A polymorphic pattern in which symptoms change within hours or days is the core of the diagnosis.

Absence of schizophrenia-specific symptoms: Schneider first-rank symptoms—thought insertion, thought withdrawal, thought broadcasting, somatic passivity experiences, feeling passivity experiences, affect passivity experiences, volition passivity experiences, third-person auditory hallucinations—do not appear. This is the key criterion distinguishing F23.0 from F23.1 (acute polymorphic psychotic disorder with symptoms of schizophrenia).

Duration: symptoms do not last 3 months or longer. Most recover completely within several weeks. If symptoms last 3 months or longer, reclassification into another diagnosis (schizophrenia, schizoaffective disorder, mood disorder, etc.) is considered.


7. Signs

The clinical signs of F23.0 differ between the acute phase and the recovery phase, and severe confusion and agitation are prominent in the acute phase.

Physical findings in the acute phase: severe agitation and anxiety, purposeless hyperactivity, and a state of confusion are observed. Sleep disturbance (complete insomnia or severe insomnia) almost always accompanies. Food refusal and inability to care for oneself may appear. Signs of autonomic hyperactivity such as heightened arousal, sweating, and tachycardia may be observed.

Mental status examination (MSE) findings: appearance may be disorganized and untidy. Speech is disorganized, with rapid changes of topic. Thought content is changeable, and hallucinations (especially auditory and visual) are reported. Affect is extremely unstable and changes rapidly. Insight is absent or very poor. Disorientation may accompany.

Neurological findings: generally no abnormality. If neurological abnormalities are found, differentiation of organic causes (encephalitis, metabolic encephalopathy, etc.) is urgent.

Signs in the recovery phase: acute-phase symptoms decrease rapidly and normal functioning is recovered within several days to weeks. During recovery, confusion about the memory of symptoms and partial amnesia may appear. Transient depressed mood may accompany after the episode.


8. Screening

Since F23.0 is an acute-onset condition, immediate evaluation of patients who develop acute psychotic symptoms is key, rather than screening of the general population.

Emergency evaluation: immediate psychiatric evaluation is needed in all cases in which acute psychotic symptoms (hallucinations, delusions, severe confusion, extreme behavior) appear. Early evaluation through emergency room psychiatric consultation or crisis mental health services hastens the start of treatment.

Tests to exclude organic causes: when acute psychosis appears, immediate exclusion of organic causes is essential. Blood glucose (hypoglycemia), electrolytes (hyponatremia, hypercalcemia), thyroid function, renal function, liver function, blood cell counts, urine drug screening, brain CT or MRI (to exclude brain lesions), EEG (to exclude epilepsy), and cerebrospinal fluid examination (when exclusion of encephalitis is needed) are performed. Autoimmune encephalitis (anti-NMDAR antibody encephalitis, etc.) has also recently emerged as an important differential diagnosis of acute psychosis.

Assessment of symptom severity: symptom severity is quantified and treatment response tracked through PANSS (Positive and Negative Syndrome Scale), BPRS (Brief Psychiatric Rating Scale), and CGI (Clinical Global Impression). Assessment of risk of harm to self and others (C-SSRS, structured clinical interview) is essential for establishing an immediate safety plan.


9. Diagnosis

The diagnosis of F23.0 follows ICD-10 criteria and is made by confirming four core elements: acute onset, polymorphic symptoms, absence of schizophrenia-specific symptoms, and a course of less than 3 months.

ICD-10 F23.0 diagnostic criteria: ① acute onset within 2 weeks; ② rapidly changing polymorphic symptoms (hallucinations, delusions, confusion, and mood changes fluctuating within days); ③ absence of Schneider first-rank symptoms or schizophrenia-specific thought disorder (thought insertion, thought broadcasting, etc.); ④ symptoms do not last 3 months or longer; ⑤ not explained by organic causes (brain lesion, metabolic abnormality, drugs); ⑥ criteria for schizophrenia or a mood disorder are not met.

Acute stress specifier of ICD-10: when there was a clear psychosocial stress event before the 2 weeks preceding onset, it is specified as 'with associated acute stress (F23.x1).' This specifier reflects the characteristics of reactive psychosis, and the presence or absence of the precipitating stress has clinical significance for prognosis and treatment.

Differential diagnosis: the main differential diagnoses are schizophrenia (symptom duration of 1 month or longer, Schneider symptoms present), F23.1 (acute polymorphic with schizophrenia-specific symptoms), psychosis with mood disorder (mood episode predominant), organic psychosis (brain lesion, metabolic abnormality, autoimmune encephalitis), substance-induced psychosis (positive drug screening), and dissociative disorders (dissociative stupor, etc.). It is conceptually similar to DSM-5 brief psychotic disorder but differs in the duration criterion.


10. Treatment

The goals of F23.0 treatment are control of acute-phase symptoms, ensuring patient safety, and resolving stress precipitants. Because the prognosis is favorable, short-term intensive treatment rather than long-term drug treatment is aimed for.

Environmental intervention: providing a quiet and safe environment, blocking excessive stimulation, and consistent staffing reduce the patient's confusion and anxiety. Visits are encouraged so that the family can serve as a reassuring presence, but excessive stimulation is avoided. Improving the sleep environment and restoring sleep are important for symptom relief.

Antipsychotics: short-term antipsychotic administration is recommended to control acute-phase agitation and psychotic symptoms. Low-dose atypical antipsychotics (olanzapine, risperidone, quetiapine) are the initial choice. When symptoms improve rapidly, the medication is tapered gradually, and although there is as yet no consensus on the duration of maintenance treatment after complete remission, tapering and discontinuation are generally considered after several months (3-6 months). Discontinuing medication too early after the first episode may raise the risk of relapse.

Benzodiazepines: to control acute agitation and insomnia, short-term benzodiazepines (lorazepam, clonazepam) may be combined with antipsychotics. Considering the risk of dependence with long-term use, they are tapered after the acute phase.

Psychosocial treatment: after acute-phase recovery, counseling and psychotherapy about stress precipitants contribute to strengthening recovery and preventing relapse. These include education on early warning signs of relapse, training in stress coping skills, and family education. Supportive counseling for serious stressful events (bereavement, job loss) helps resolve the precipitating stress.


11. Prognosis

The prognosis of F23.0 is the most favorable even within the F23 group, and complete recovery is expected in most patients.

Short-term prognosis: in most F23.0 patients, symptoms resolve completely within several weeks to months. Depending on the study, about 70-90% of patients reach complete remission within 3 months of the first episode. This contrasts markedly with the recovery rate of schizophrenia (about 20-30%).

Relapse rate: the relapse rate after the first episode is about 30-50%, so relapse is not uncommon. Relapse is generally again associated with an acute stressful event, and often shows a course and prognosis similar to the previous episode. In most cases, even with repeated episodes, the condition does not develop into schizophrenia.

Diagnostic transition: in some F23.0 patients, the diagnosis later transitions to schizophrenia, schizoaffective disorder, or bipolar disorder. In long-term follow-up studies, transition to schizophrenia is reported in about 10-15%. Family history of schizophrenia, accompanying negative symptoms, and decline in premorbid social functioning are risk factors for transition.

Functional prognosis: after complete remission, functioning is generally restored to the pre-episode level. Even with repeated episodes, functioning between episodes is often generally maintained. Accidents that occurred during a severe episode (traffic accident, fall, drowning, etc.) or the consequences of behavior can affect long-term functioning.


12. Prevention

Prevention of F23.0 focuses mainly on risk factor management and relapse prevention. Prevention of the first episode centers on acute stress management and support for vulnerable groups.

Stress management: prompt psychological support for vulnerable individuals experiencing severe psychosocial stress (bereavement, job loss, difficulty adjusting after immigration, etc.) contributes to prevention of F23.0. Grief counseling, crisis intervention services, and vocational rehabilitation programs serve to buffer psychosocial stress. Mental health support programs for immigrants are important for reducing incidence in this group.

Sleep hygiene education: because sleep deprivation raises vulnerability to psychosis, the importance of sleep management is taught in the postpartum period, to shift workers, and in extreme stress situations. Postpartum support services for the prevention of postpartum psychosis (mental health screening, sleep support, family support) are important.

Relapse prevention: after the experience of a first episode, education about warning symptoms of relapse (decreased sleep, mood instability, social withdrawal) enables early intervention. In patients at high risk of relapse, an individualized discussion of the benefits and risks of preventive maintenance drug treatment is needed.


13. References

  1. Pillmann F, Haring A, Balzuweit S, Marneros A. Bouffée délirante and ICD-10 acute and transient psychoses: a comparative study. Australian & New Zealand Journal of Psychiatry. 2003;37(3):327-333. DOI: 10.1046/j.1440-1614.2003.01175.x. PMID: 12780471.

  2. Marneros A, Pillmann F, Haring A, Balzuweit S, Blöink R. Features of acute and transient psychotic disorders. European Archives of Psychiatry and Clinical Neuroscience. 2003;253(4):167-174. DOI: 10.1007/s00406-003-0420-y. PMID: 12920591.

  3. Jorgensen P, Bennedsen B, Christensen J, Hyllested A. Acute and transient psychotic disorder: a 1-year follow-up study. Acta Psychiatrica Scandinavica. 1997;96(2):99-104. DOI: 10.1111/j.1600-0447.1997.tb09910.x. PMID: 9272193.

  4. Singh SP, Burns T, Amin S, Jones PB, Harrison G. Acute and transient psychotic disorders: precursors, epidemiology, course and outcome. British Journal of Psychiatry. 2004;185:452-459. DOI: 10.1192/bjp.185.6.452. PMID: 15572741.

  5. Castagnini A, Berrios GE. Acute and transient psychotic disorders (ICD-10 F23): a review from a European perspective. European Archives of Psychiatry and Clinical Neuroscience. 2009;259(8):433-443. DOI: 10.1007/s00406-009-0008-3. PMID: 19247624.

  6. Susser E, Wanderling J. Epidemiology of nonaffective acute remitting psychosis vs schizophrenia. Archives of General Psychiatry. 1994;51(4):294-301. DOI: 10.1001/archpsyc.1994.03950040038004. PMID: 8161289.

  7. Pillmann F, Haring A, Balzuweit S, Blöink R, Marneros A. The concordance of ICD-10 acute and transient psychoses and DSM-IV brief psychotic disorder. Psychological Medicine. 2002;32(3):525-533. DOI: 10.1017/S003329170200529X. PMID: 11989997.

  8. Sajith SG, Chandrasekaran R, Unni KE, Sahai A. Acute polymorphic psychotic disorder: differences from acute schizophrenia and role of stress. Psychopathology. 2002;35(1):28-35. DOI: 10.1159/000056227. PMID: 11893847.

  9. Murray RM, Van Os J. Predictors of outcome in schizophrenia. Journal of Clinical Psychopharmacology. 1998;18(2 Suppl 1):2S-4S. PMID: 9541145.

  10. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: WHO; 1992. (See the F23.0 classification criteria.)